All Photos(1)

Documents

1368609

USP

Lisinopril

Name: Lisinopril
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₁H₃₁O₅N₃ · 2H₂O

CAS Number:

83915-83-7

Molecular Weight:

441.52

MDL number:

MFCD01698825

UNSPSC Code:

41116107

PubChem Substance ID:

329750250

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

lisinopril

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

InChI key

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lisinopril USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Lisinopril and Hydrochlorothiazide Tablets
Lisinopril Compounded Oral Suspension
Lisinopril Tablets

Biochem/physiol Actions

Angiotensin converting enzyme (ACE) inhibitor.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1368610

BP695

Lisinopril dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2239

Lisinopril Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2495

Lisinopril Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

GHS08

Signal Word

Danger

Hazard Statements

H360D,H373

Precautionary Statements

P202 - P260 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1A - STOT RE 2

Target Organs

Kidney

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Development of an Australian version of the Alcohol-Related Problems Survey: a comprehensive computerised screening tool for older adults.

Stephen J Bright et al.

Australasian journal on ageing, 34(1), 33-37 (2013-10-15)

The Alcohol-Related Problems Survey (ARPS) reliably classifies drinking as non-hazardous, hazardous or harmful using scoring algorithms that consider quantity and frequency of alcohol use alone and in combination with health conditions, medication-use and functional status. Because it has been developed

Lisinopril: a review of its use in congestive heart failure.

K Simpson et al.

Drugs, 59(5), 1149-1167 (2000-06-14)

The ACE inhibitor lisinopril is a lysine derivative of enalaprilat, the active metabolite of enalapril. In patients with heart failure, maximum pharmacodynamic effects are produced 6 to 8 hours after administration of the drug and persist for 12 to 24

Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema.

M F Abdelmalek et al.

Digestive diseases and sciences, 42(4), 847-850 (1997-04-01)

Comparison of lisinopril and captopril in the treatment of left ventricular congestive heart failure--influence of duration of action on efficacy and safety.

T D Giles

Zeitschrift fur Kardiologie, 80 Suppl 2, 35-39 (1991-01-01)

Data from the lisinopril-captopril comparison trial (6), as well as other data (1, 8, 14, 10) indicate that both long- and short-acting ACEI are effective and safe for the treatment of CHF. An improved effect on LV function and signs

Effects of lisinopril on cardiac contractility and ionic currents.

C Valenzuela et al.

General pharmacology, 25(5), 825-832 (1994-09-01)

1. The effects of lisinopril, an angiotensin-converting enzyme inhibitor, were studied on cardiac contractile force, action potential characteristics and membrane ionic currents. 2. In guinea-pig atria, lisinopril (0.001-1 microM) exerted a negative inotropic effect which was accompanied by a shortening

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service